SELECTing Treatments for Cardiovascular Disease — Obesity in the Spotlight

This editorial discusses the global obesity epidemic and its significant role in cardiovascular disease (CVD). It highlights the SELECT trial, which demonstrated that semaglutide, a GLP-1 receptor agonist, reduces CVD risk in individuals with overweight or obesity but without diabetes. The trial showed a 20% reduction in cardiovascular events and a 9.4% average weight loss. The authors emphasize the need for broader access to such treatments, alongside addressing socioeconomic and environmental factors contributing to obesity. They also call for more inclusive research to ensure equitable healthcare outcomes.

This editorial discusses the global obesity epidemic and its significant role in cardiovascular disease (CVD). It highlights the SELECT trial, which demonstrated that semaglutide, a GLP-1 receptor agonist, reduces CVD risk in individuals with overweight or obesity but without diabetes. The trial showed a 20% reduction in cardiovascular events and a 9.4% average weight loss. The authors emphasize the need for broader access to such treatments, alongside addressing socioeconomic and environmental factors contributing to obesity. They also call for more inclusive research to ensure equitable healthcare outcomes.